Renal Function Can Improve at Any Stage of Chronic Kidney Disease

Introduction Even though renal function decline is considered relentless in chronic kidney disease (CKD), improvement has been shown in patients with hypertensive nephropathy. Whether this can occur in any type of nephropathy and at any stage is unknown as are the features of patients who improve. Methods We identified 406 patients in the NephroTest cohort with glomerular filtration rates (mGFR) measured by 51Cr-EDTA clearance at least 3 times during at least 2 years of follow-up. Individual examination of mGFR trajectories by 4 independent nephrologists classified patients as improvers, defined as those showing a sustained mGFR increase, or nonimprovers. Twelve patients with erratic trajectories were excluded. Baseline data were compared between improvers and nonimprovers, as was the number of recommended therapeutic targets achieved over time (specifically, for systolic and diastolic blood pressure, proteinuria, and use of renin angiotensin system blockers). Results Measured GFR improved over time in 62 patients (15.3%). Their median mGFR slope was +1.88[IQR 1.38, 3.55] ml/min/year; it was −2.23[−3.9, −0.91] for the 332 nonimprovers. Improvers had various nephropathies, but not diabetic glomerulopathy or polycystic kidney disease. They did not differ from nonimprovers for age, sex, cardiovascular history, or CKD stage, but their urinary albumin excretion rate was lower. Improvers achieved significantly more recommended therapeutic targets (2.74±0.87) than nonimprovers (2.44±0.80, p<0.01). They also had fewer CKD-related metabolic complications and a lower prevalence of 25OH-vitamin-D deficiency. Conclusion GFR improvement is possible in CKD patients at any CKD stage through stage 4–5. It is noteworthy that this GFR improvement is associated with a decrease in the number of metabolic complications over time.

[1]  B. Astor,et al.  Kidney function can improve in patients with hypertensive CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[2]  F. Dekker,et al.  High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Fogo,et al.  Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. , 1991, Kidney international.

[4]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[5]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[6]  Bertram L Kasiske,et al.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.

[7]  R. Garrick Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes , 2011 .

[8]  Chris Jones,et al.  Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  H. Toutenburg Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .

[10]  M. Tonelli,et al.  Progression of kidney dysfunction in the community-dwelling elderly. , 2006, Kidney international.

[11]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[12]  Javier Zamora,et al.  Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  D. Kohan,et al.  Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[14]  S. Nielsen,et al.  Thirty Years with HIV Infection—Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors , 2012, AIDS research and treatment.

[15]  J. Boffa,et al.  Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  Liang Li,et al.  Longitudinal progression trajectory of GFR among patients with CKD. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  T. Akizawa,et al.  Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[18]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[19]  N. Powe,et al.  25-hydroxyvitamin D levels, race, and the progression of kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[20]  G. Remuzzi,et al.  Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. , 2011, Journal of the American Society of Nephrology : JASN.

[21]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[22]  Olivier Moranne,et al.  Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[23]  B. Eriksen,et al.  The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. , 2006, Kidney international.

[24]  M. Donohue,et al.  Pirfenidone for diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[25]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[26]  Ann M. Johnson,et al.  Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  H. Taskapan,et al.  Improvement in eGFR in patients with chronic kidney disease attending a nephrology clinic , 2008, International Urology and Nephrology.

[28]  B. Kestenbaum,et al.  Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[29]  G. Remuzzi,et al.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.

[30]  K. Kalantar-Zadeh,et al.  Association of disorders in mineral metabolism with progression of chronic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[31]  G. Remuzzi,et al.  ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.

[32]  A. Zeringue,et al.  Rate of kidney function decline associates with mortality. , 2010, Journal of the American Society of Nephrology : JASN.

[33]  M. Raftery,et al.  Bicarbonate supplementation slows progression of CKD and improves nutritional status. , 2009, Journal of the American Society of Nephrology : JASN.

[34]  P. Houillier,et al.  Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  T. Sakurai,et al.  Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. , 2010, The Journal of clinical investigation.

[36]  C. Zoccali,et al.  Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.

[37]  P. Houillier,et al.  Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[39]  G. Beck,et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.

[40]  E. Ritz,et al.  Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. , 2003, Journal of the American Society of Nephrology : JASN.

[41]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[42]  D. Bates,et al.  Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.